Literature DB >> 20732516

Prognostic factors and family history for survival of esophageal squamous cell carcinoma patients after surgery.

Jiang Yuequan1, Chen Shifeng, Zhu Bing.   

Abstract

BACKGROUND: Surgical resection is the most effective treatment for patients with isolated esophageal cancer, but the 5-year survival rate is still very poor in spite of recent advances in early diagnosis and extended lymphadenectomy. To identify the high-risk group and the factors affecting postoperative course, we analyzed the prognostic factors including the family history of esophageal cancer in survival after esophagectomy.
METHODS: A total of 1,553 patients with esophageal squamous cell carcinoma after surgery were the subject of the present study. Thirty-one percent of all these patients have family history of esophageal cancer. The prognostic factors analyzed in this study included age, sex, tumor size, tumor location, lymphadenopathy, histologic type, grade of differentiation, stage of cancer, adjuvant treatments, and family history of esophageal cancer.
RESULTS: The overall 3-year and 5-year postoperative survival rates were 43.7% and 26.2%, respectively, for all patients with esophagectomy. The five prognostic factors determined as significant by univariate p value were tumor size, lymphadenopathy, grade of differentiation, stage of cancer, and family history of esophageal cancer. Multivariate analysis showed that the independent prognostic factors were tumor size, grade of differentiation, stage of cancer, and family history of esophageal cancer. Our study also found that patients in groups with mid and upper segment esophageal squamous cell carcinoma, smaller tumor size, earlier stage of cancer, and poor differentiation of tumor cells had a significantly higher rate of positive family history than in the other groups, respectively.
CONCLUSIONS: Tumor size, grade of differentiation, lymphadenopathy, stage of cancer, and family history of esophageal cancer were identified as prognostic factors after esophagectomy. Family history of esophageal cancer is an important prognostic factor that surgeons should take into consideration when selecting a treatment method. 2010 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20732516     DOI: 10.1016/j.athoracsur.2010.05.060

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  45 in total

1.  Prognostic value of the neutrophil-to-lymphocyte ratio for overall and disease-free survival in patients with surgically treated esophageal squamous cell carcinoma.

Authors:  Joonho Jung; Seong Yong Park; Soo-Jin Park; Jiye Park
Journal:  Tumour Biol       Date:  2015-12-12

2.  The Number of Harvested LNs Is an Independent Prognostic Factor in Lymph Node Metastasis-negative Patients Who Received Curative Esophagectomy.

Authors:  Toru Aoyama; Yosuke Atsumi; Shinnosuke Kawahara; Hiroshi Tamagawa; Ayako Tamagawa; Yukio Maezawa; Kazuki Kano; Masaaki Murakawa; Keisuke Kazama; Masakatsu Numata; Takashi Oshima; Norio Yukawa; Munetaka Masuda; Yasushi Rino
Journal:  In Vivo       Date:  2020 Jul-Aug       Impact factor: 2.155

3.  Identification of microRNAs as novel biomarkers for detecting esophageal squamous cell carcinoma in Asians: a meta-analysis.

Authors:  Yanying Wang; Qingxiu Wang; Na Zhang; Hong Ma; Yuchun Gu; Hongming Tang; Zengguang Xu; Yong Gao
Journal:  Tumour Biol       Date:  2014-08-19

4.  miR-204 inhibits invasion and epithelial-mesenchymal transition by targeting FOXM1 in esophageal cancer.

Authors:  Yurong Sun; Xiuwen Yu; Qingyang Bai
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

Review 5.  NEAT1: A novel cancer-related long non-coding RNA.

Authors:  Xin Yu; Zheng Li; Heyi Zheng; Matthew T V Chan; William Ka Kei Wu
Journal:  Cell Prolif       Date:  2017-01-19       Impact factor: 6.831

6.  The Lymph Node Ratio Is an Independent Prognostic Factor in Esophageal Cancer Patients Who Receive Curative Surgery.

Authors:  Norio Yukawa; Toru Aoyama; Hiroshi Tamagawa; Ayako Tamagawa; Yosuke Atsumi; Shinnosuke Kawahara; Yukio Maezawa; Kazuki Kano; Masaaki Murakawa; Keisuke Kazama; Masakatsu Numata; Takashi Oshima; Munetaka Masuda; Yasushi Rino
Journal:  In Vivo       Date:  2020 Jul-Aug       Impact factor: 2.155

7.  Esophageal cancer stem cells are suppressed by tranilast, a TRPV2 channel inhibitor.

Authors:  Atsushi Shiozaki; Michihiro Kudou; Daisuke Ichikawa; Hitoshi Fujiwara; Hiroki Shimizu; Takeshi Ishimoto; Tomohiro Arita; Toshiyuki Kosuga; Hirotaka Konishi; Shuhei Komatsu; Kazuma Okamoto; Yoshinori Marunaka; Eigo Otsuji
Journal:  J Gastroenterol       Date:  2017-04-07       Impact factor: 7.527

8.  PET/CT predicts survival in patients undergoing primary surgery for esophageal cancer.

Authors:  Kirsten Lindner; Daniel Palmes; Norbert Senninger; Richard Hummel
Journal:  Langenbecks Arch Surg       Date:  2015-01-09       Impact factor: 3.445

9.  Knockdown of UCHL3 inhibits esophageal squamous cell carcinoma progression by reducing CRY2 methylation.

Authors:  Jijun Xue; Jinyuan Yi; Xiaolong Zhu
Journal:  Hum Cell       Date:  2022-01-28       Impact factor: 4.174

Review 10.  AFAP1-AS1: A novel oncogenic long non-coding RNA in human cancers.

Authors:  Fuyou Zhang; Jianfa Li; Huizhong Xiao; Yifan Zou; Yuchen Liu; Weiren Huang
Journal:  Cell Prolif       Date:  2017-10-22       Impact factor: 6.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.